Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
Chimerix, Inc. (CMRX)
Last chimerix, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.chimerix.com/investor-relations
Company Research
Source: GlobeNewswire
DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for a rolling submission of its New Drug Application (NDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox. The Company intends to begin the rolling NDA submission for BCV in May 2020 with completion targeted for mid-2020. Chimerix is developing BCV as a potential medical countermeasure for smallpox under an ongoing collaboration and funding provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, under ongoing USG Contract No HHSO10201100013C. “The value of being prepared for viral outbreaks has ne
Show less
Read more
Impact Snapshot
Event Time:
CMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMRX alerts
High impacting Chimerix, Inc. news events
Weekly update
A roundup of the hottest topics
CMRX
News
- Glioma Pipeline Landscape Report 2024: Comprehensive Market Insights on 180+ Companies and Respective 200+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024 [Yahoo! Finance]Yahoo! Finance
- Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024GlobeNewswire
- Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
CMRX
Earnings
- 2/29/24 - Beat
CMRX
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 3/21/24 - Form 4
- CMRX's page on the SEC website